STAMFORD,wic office silver city nm Conn., May 04, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (
CARA
), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, May 11, 2020, at 4:30 p.m. ET to report first quarter 2020 financial results and provide a corporate update.
To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 3875739. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at
www.CaraTherapeutics.com
.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with CKD, atopic dermatitis and primary biliary cholangitis (PBC).
The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
INVESTOR CONTACT:
Jane Urheim
Stern Investor Relations, Inc.
212-362-1200
View comments
顶: 85664踩: 25
【wic office silver city nm】Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020
人参与 | 时间:2024-09-29 12:25:47
相关文章
- Trump threatens to deploy U.S. military to quell riots across the country
- Introducing Freshpet (NASDAQ:FRPT), The Stock That Soared 463% In The Last Three Years
- Should You Be Tempted To Sell American States Water Company (NYSE:AWR) Because Of Its P/E Ratio?
- Does Vectrus, Inc. (NYSE:VEC) Have A High Beta?
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesa Air Group, Inc. - MESA
- UK minister defends giving Brexit ferry contract to company with no ships
- How Does Investing In Geox S.p.A. (BIT:GEO) Impact The Volatility Of Your Portfolio?
- January ETF Asset Report
- Robin.io Expands Leadership Team and Advisory Board for 5G Market
- Wall Street Week Ahead: Fed pause validates market fears about U.S. growth
评论专区